Comprehensive analysis of INHBA: A biomarker for anti-TGFβ treatment in head and neck cancer.

Shunhao Zhang, Keyu Jin, Tianle Li, Maolin Zhou, Wenbin Yang

Experimental biology and medicine (Maywood, N.J.) 2022 Aug

filter terms:

Inhibin subunit βA (INHBA) is a protein-coding gene belonging to the transforming growth factor β (TGFβ) superfamily, which is associated with the development of a variety of cancers. However, the role of INHBA in head and neck squamous cell carcinoma (HNSC) remains unclear. The expression profile and prognostic significance of INHBA in HNSC were assessed using a variety of informatics methods. The level of INHBA expression was significantly higher in patients with HNSC, and it was correlated with sex, tumor-node-metastasis (TNM) stage, histological grade, and human papillomavirus (HPV) status. Kaplan-Meier (K-M) analysis indicated that poor overall survival (OS) and disease-free survival (DFS) were significantly associated with INHBA upregulation in HNSC. INHBA overexpression was validated as an independent poor prognostic factor by multivariate Cox regression, and including INHBA expression level in the prognostic model could increase prediction accuracy. In addition, copy number alterations (CNAs) of INHBA and miR-217-5p downregulation are potential mechanisms for elevated INHBA expression in HNSC. In conclusion, INHBA may represent a promising predictive biomarker and candidate target for anti-TGFβ therapy in HNSC.

Citation

Shunhao Zhang, Keyu Jin, Tianle Li, Maolin Zhou, Wenbin Yang. Comprehensive analysis of INHBA: A biomarker for anti-TGFβ treatment in head and neck cancer. Experimental biology and medicine (Maywood, N.J.). 2022 Aug;247(15):1317-1329